Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141(+) dendritic cells to activate naïve and memory WT1‐specific CD8(+) T cells

OBJECTIVES: Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8(+) T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141(+) dendritic cells (DCs). The C‐type lectin‐like receptor CLEC9A is expressed exclus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Immunology
Main Authors: Pearson, Frances E, Tullett, Kirsteen M, Leal‐Rojas, Ingrid M, Haigh, Oscar L, Masterman, Kelly‐Anne, Walpole, Carina, Bridgeman, John S, McLaren, James E, Ladell, Kristin, Miners, Kelly, Llewellyn‐Lacey, Sian, Price, David A, Tunger, Antje, Schmitz, Marc, Miles, John J, Lahoud, Mireille H, Radford, Kristen J
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292901/
https://ncbi.nlm.nih.gov/pubmed/32547743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados